Advances in Gene-based Vaccine Platforms to Address the COVID-19 Pandemic

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2021 Jan 10

PMID 33422546

Citations 45

Authors

Deborah Pushparajah

Salma Jimenez

Shirley Wong

Hibah Alattas

Nafiseh Nafissi

Roderick A Slavcev

Affiliations

Soon will be listed here.

Abstract

The novel betacoronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread across the globe at an unprecedented rate since its first emergence in Wuhan City, China in December 2019. Scientific communities around the world have been rigorously working to develop a potent vaccine to combat COVID-19 (coronavirus disease 2019), employing conventional and novel vaccine strategies. Gene-based vaccine platforms based on viral vectors, DNA, and RNA, have shown promising results encompassing both humoral and cell-mediated immune responses in previous studies, supporting their implementation for COVID-19 vaccine development. In fact, the U.S. Food and Drug Administration (FDA) recently authorized the emergency use of two RNA-based COVID-19 vaccines. We review current gene-based vaccine candidates proceeding through clinical trials, including their antigenic targets, delivery vehicles, and route of administration. Important features of previous gene-based vaccine developments against other infectious diseases are discussed in guiding the design and development of effective vaccines against COVID-19 and future derivatives.

Citing Articles

Designing of an innovative conserved multiepitope subunit vaccine targeting SARS-CoV-2 glycoprotein and nucleoprotein through immunoinformatic.

Adelusi T, Ogunlana A, Oyewole M, Ojo T, Olaoba O, Oladipo E Sci Rep. 2025; 15(1):2563.

PMID: 39833186 PMC: 11747174. DOI: 10.1038/s41598-024-72495-9.

Coronavirus Anatomy and Its Analytical Approaches for Targeting COVID-19.

Ramanathan S, Malarvili M, Gopinath S, Nindhia T Adv Exp Med Biol. 2024; 1457:33-44.

PMID: 39283419 DOI: 10.1007/978-3-031-61939-7_2.

Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles.

Bodnar K, Feher P, Ujhelyi Z, Bacskay I, Jozsa L Pharmaceutics. 2024; 16(4).

PMID: 38675110 PMC: 11054466. DOI: 10.3390/pharmaceutics16040449.

Transfection of hypoxia-inducible factor-1α mRNA upregulates the expression of genes encoding angiogenic growth factors.

Wlodarczyk J, Leng A, Nourmohammadi Abadchi S, Shababi N, Mokhtari-Esbuie F, Gheshlaghi S Sci Rep. 2024; 14(1):6738.

PMID: 38509125 PMC: 10954730. DOI: 10.1038/s41598-024-54941-w.

Evaluation of Seroconversion Rate Following SARS COV 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences.

Alavi M, Mousavi M, Jazayeri M, Ebadifar A Avicenna J Med Biotechnol. 2023; 15(4):258-263.

PMID: 38078340 PMC: 10709755. DOI: 10.18502/ajmb.v15i4.13501.

References

Liu M . A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019; 7(2). PMC: 6631684. DOI: 10.3390/vaccines7020037. View

Antrobus R, Coughlan L, Berthoud T, Dicks M, Hill A, Lambe T . Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2013; 22(3):668-674. PMC: 3944330. DOI: 10.1038/mt.2013.284. View

Folegatti P, Bittaye M, Flaxman A, Lopez F, Bellamy D, Kupke A . Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826. PMC: 7172901. DOI: 10.1016/S1473-3099(20)30160-2. View

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Hellfritzsch M, Scherliess R . Mucosal Vaccination via the Respiratory Tract. Pharmaceutics. 2019; 11(8). PMC: 6723941. DOI: 10.3390/pharmaceutics11080375. View

Tang D, DeVit M, Johnston S . Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356(6365):152-4. DOI: 10.1038/356152a0. View

Tebas P, Kraynyak K, Patel A, Maslow J, Morrow M, Sylvester A . Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis. 2019; 220(3):400-410. DOI: 10.1093/infdis/jiz132. View

Damjanovic D, Zhang X, Mu J, Medina M, Xing Z . Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector. Genet Vaccines Ther. 2008; 6:5. PMC: 2259349. DOI: 10.1186/1479-0556-6-5. View

10.

Becker Y . Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review. Virus Genes. 2006; 33(2):235-52. DOI: 10.1007/s11262-006-0064-x. View

11.

Hu M, Jones T, Kenney R, Barnard D, Burt D, Lowell G . Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine. 2007; 25(34):6334-40. PMC: 7115497. DOI: 10.1016/j.vaccine.2007.06.017. View

12.

Dutta N, Mazumdar K, Gordy J . The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94(13). PMC: 7307180. DOI: 10.1128/JVI.00647-20. View

13.

Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357. PMC: 5584442. DOI: 10.1073/pnas.1707304114. View

14.

Liljeroos L, Malito E, Ferlenghi I, Bottomley M . Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. J Immunol Res. 2015; 2015:156241. PMC: 4615220. DOI: 10.1155/2015/156241. View

15.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

16.

Bonnotte B, Gough M, Phan V, Ahmed A, Chong H, Martin F . Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Res. 2003; 63(9):2145-9. View

17.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

18.

Quirk E, Brown E, Leavitt R, Mogg R, Mehrotra D, Evans R . Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants. Open Forum Infect Dis. 2015; 1(1):ofu016. PMC: 4324197. DOI: 10.1093/ofid/ofu016. View

19.

Ferreira G, Monteiro G, Prazeres D, Cabral J . Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. Trends Biotechnol. 2000; 18(9):380-8. DOI: 10.1016/s0167-7799(00)01475-x. View

20.

Mubarak A, Alturaiki W, Hemida M . Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019; 2019:6491738. PMC: 6476043. DOI: 10.1155/2019/6491738. View